Regulatory News:

STENTYS (FR0010949404 - STNT) (Paris:STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces its revenues and cash position at June 30, 2016.

• Change in revenues*

* Unaudited data

Over the second quarter of 2016, STENTYS continued to deliver a solid commercial performance with revenues up 41% to €2.1 million. This growth momentum again reflects the demand from cardiologists for the Xposition stents. Over the first half of 2016, STENTYS recorded a 40% increase in sales to €3.6 million.

• A secure financial structure

At June 30, 2016, STENTYS had a cash position of €18.3 million.

Christophe Lottin, Chief Executive Officer of STENTYS, comments: “This significant increase in revenues for the sixth consecutive quarter shows how STENTYS team is able to build the Company’s growth with a strategy of product differentiation. I strongly believe that the Self-Apposing technology, combined with the easier delivery technique from the new catheter, provides a unique benefit to cardiologists and their patients, which is to guarantee perfect implantation in complex coronary pathologies.”

• Upcoming financial publication

STENTYS expects to publish its financial results for the first half of 2016 on September 15, 2016.

About STENTYS
STENTYS is developing and commercializing innovative solutions for the treatment of patients with complex artery disease. STENTYS’ Self-Apposing® drug-eluting stents are designed to adapt to vessels with ambiguous or fluctuating diameters in order to prevent the malapposition problems associated with conventional stents. The APPOSITION clinical trials in the treatment of acute myocardial infarction showed a very low one year mortality rate and a faster arterial healing compared to conventional stents. The company’s product portfolio also includes MiStent SES®, a coronary DES whose new drug delivery mechanism is designed to match vessel response, and is marketed through STENTYS’ commercial network in Europe, the Middle East, Asia and Latin America.
More information is available at www.stentys.com

Safe Harbor Statements
This press release contains forward-looking statements about the Company that are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which it will operate in the future which may not be accurate. Such forward-looking statements involve known and unknown risks which may cause the Company’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with the development and commercialization of the Company’s products, market acceptance of the Company’s products, its ability to manage growth, the competitive environment in relation to its business area and markets, its ability to enforce and protect its patents and proprietary rights, uncertainties related to the U.S. FDA approval process, slower than expected rates of patient recruitment for clinical trials, the outcome of clinical trials, and other factors, including those described in the Section 4 “Risk Factors” of the Company’s 2014 Registration Document (document de référence) filed with the French Autorité des Marchés Financiers (AMF) on July 29, 2015 under number D.15-0807 and as updated in section 4.1 of the Registration Document Update filed with the AMF on February 11, 2016 under number D.15-0807-A01.

STENTYS is listed on Compartment C of Euronext Paris
ISIN: FR0010949404 – Ticker: STNT

View source version on businesswire.com: http://www.businesswire.com/news/home/20160712006270/en/